Treatment response, survival, and safety profile of camrelizumab plus apatinib regimen as third-line treatment in metastatic gastric cancer patients

Ning Ma, Hui Qiao, Hanchuan Tao, Xinli Gan, Zhili Shan, Xiaomin Chen, Xiaojun Zhou

2022Clinics and Research in Hepatology and Gastroenterology15 citationsDOI

Topics & Concepts

ApatinibMedicineRegimenOncologyInternal medicineCancerOverall survivalGastric Cancer Management and OutcomesCancer Immunotherapy and BiomarkersCholangiocarcinoma and Gallbladder Cancer Studies